Arrowhead Cleared By FDA For Phase 2b Hepatitis B Study
April 13, 2015 at 23:30 PM EDT
The drug known as ARC-520 has been cleared by the FDA to proceed with multi-dose trial in hepatitis B patients but shares only briefly rallied before returning flat.